PT  - JOURNAL ARTICLE
AU  - Deng, Zheng
AU  - Xuan, Yan
AU  - Li, Xinxing
AU  - Crawford, William J
AU  - Yuan, Zhiqing
AU  - Chen, Zhoukan
AU  - Brooks, Anastasia
AU  - Liang, Xiaowen
AU  - Wang, Haolu
AU  - Chen, Tao
TI  - Effect of metabolic syndrome components on the risk of malignancy in patients with gallbladder lesions
AID  - 10.1101/2020.06.06.20123992
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.06.06.20123992
4099  - http://medrxiv.org/content/early/2020/06/07/2020.06.06.20123992.short
4100  - http://medrxiv.org/content/early/2020/06/07/2020.06.06.20123992.full
AB  - Background and Aims The malignant potential of gallbladder lesions is debated, and there is limited guidance on surveillance. Predicting their risk of malignancy could help clinicians manage and potentially improve prognosis. We evaluated the independent and joint effects of metabolic syndrome components on the risk of malignancy among patients with gallbladder lesions.Methods Using a multicenter database, consecutive patients with pathologically confirmed gallbladder lesions between 2012 and 2019 were identified. Univariate and multivariate logistic regression analyses were used to evaluate the effects of metabolic syndrome components (diabetes, hypertension, dyslipidemia, obesity) as additive or combined indicators for the risk of malignancy. Unadjusted and adjusted odds ratios were calculated.Results Of the 625 patients, 567 patients were identified with benign gallbladder lesions and 58 patients with gallbladder cancer (GBC). Among all metabolic syndrome components, the proportion of GBC patients with dyslipidemia (63.8%) was significantly greater than benign gallbladder polyps (42.2%, P = 0.002). In multivariate logistic regression analysis, dyslipidemia was associated with a 2.67-fold increase in the risk of GBC (95% confidence interval 1.17-6.09). Dyslipidemia is an independent risk factor for malignancy (adjusted odds ratio 2.164, 95% confidence interval 1.165-4.021), regardless of whether the other risk factors and metabolic syndrome components are combined. Dyslipidemia (adjusted odds ratio 2.164, 95% confidence interval 1.165-4.021) and decreased high-density lipoprotein (HDL, adjusted odds ratio 3.035, 95% confidence interval 1.645-5.600) were closely associated with increased risk of malignancy.Conclusions Dyslipidemia is associated with a 2.67-fold increase in the risk of malignancy, regardless of the presence of other metabolic syndrome components. Dyslipidemia is an independent risk factor for malignancy in patients with gallbladder lesions.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by Cultivating Funds of Renji Hospital, School of Medicine, Shanghai Jiao Tong University, PYZY16-017.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was conducted in accordance with the Declaration of Helsinki. The study protocol was approved by the Shanghai Jiaotong University School of Medicine, Renji Hospital Ethics Committee (Ethical Approval Nomber 2016-045).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are availableBGPBenign gallbladder polypsGBCGallbladder cancerTGTriglyceridesHDLHigh-density lipoproteinBMIbody mass indexORodds ratioCIconfidence intervalHDLhigh density lipoprotein